Sionna Therapeutics (NASDAQ:SION – Get Free Report)‘s stock had its “hold” rating reiterated by analysts at Stifel Nicolaus in a note issued to investors on Monday, Marketbeat Ratings reports. They presently have a $7.00 target price on the stock. Stifel Nicolaus’ price target suggests a potential upside of 65.29% from the company’s previous close.

A number of other research analysts also recently commented on SION. Raymond James Financial reiterated a “strong-buy” rating and set a $59.00 price objective on shares of Sionna Therapeutics in a report on Thursday. JonesTrading boosted their target price on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday. Finally, Guggenheim boosted their price objective on shares of Sionna Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.67.

View Our Latest Report on Sionna Therapeutics

Shares of NASDAQ:SION traded down $46.80 during midday trading on Monday, reaching $4.24. The company’s stock had a trading volume of 13,002,311 shares, compared to its average volume of 468,554. The firm has a market cap of $191.46 million, a price-to-earnings ratio of -1.92 and a beta of 1.32. The business has a 50 day moving average price of $42.35 and a 200 day moving average price of $40.42. Sionna Therapeutics has a 1 year low of $4.05 and a 1 year high of $54.97.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Sell-side analysts anticipate that Sionna Therapeutics will post -2.63 earnings per share for the current fiscal year.

In other news, Director Peter A. Thompson sold 115,844 shares of Sionna Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of Sionna Therapeutics stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the transaction, the director directly owned 2,555,877 shares in the company, valued at $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 403,726 shares of company stock worth $18,259,354. Company insiders own 5.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SION. State of Wyoming acquired a new stake in shares of Sionna Therapeutics in the second quarter worth $35,000. GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics during the 4th quarter valued at $36,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $44,000. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics during the 3rd quarter worth $30,000. Finally, Balyasny Asset Management L.P. purchased a new stake in Sionna Therapeutics during the 4th quarter worth $58,000.

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

• Five stocks we like better than Sionna Therapeutics
• Is Monster Beverage’s Best-Case Scenario Already Priced Into the Stock?
• Symbotic’s Q3 Profit Inflection Signals Underrated Growth Story
• Build Dividend Income at Low Cost With These ETFs
• 3 Major Earnings Winners You May Have Missed

Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Millicom International Cellular (NASDAQ:TIGO) Price Target Raised to $60.10

COPT Defense Properties (NYSE:CDP) versus Empire State Realty Trust (NYSE:ESRT) Head to Head Comparison